Vitamin D and Hair Loss: What the Receptor Research Actually Shows

2026년 8월 18일

By Dr. Susan Lin, MD | MD HAIR | La Cañada Ventures, Inc.

Someone told you to check your vitamin D. Maybe it was a friend who swore it fixed her shedding, maybe a wellness account with confident graphics, maybe your own physician in passing. So you looked it up, and within ten minutes you had read that vitamin D deficiency causes hair loss, that mice without the vitamin D receptor go completely bald, and that a high-dose weekly capsule from the pharmacy might be all that stands between you and your old ponytail.

Some of that is true. Some of it is a real finding stretched past what it can carry. And one part of it — the part about taking high doses on your own — is where people genuinely get hurt.

I have formulated for hair and scalp since 2008, and vitamin D is the nutrient I am asked about more than any other except iron. It deserves a careful answer, because the underlying science is genuinely fascinating and the popular version of it is genuinely misleading. Here is what the receptor research shows, what the human association studies show, where the two diverge, and what to do about your own level.

The Real Story Is the Receptor, Not the Vitamin

Start with the thing most articles skip: vitamin D is not really a vitamin. It is a prohormone. Your skin makes it from cholesterol under UVB light, your liver converts it to 25-hydroxyvitamin D (the storage form we measure), and your kidney converts that to 1,25-dihydroxyvitamin D, the active hormone.

That hormone works by binding the vitamin D receptor (VDR) — a nuclear receptor that, once activated, partners with retinoid X receptor and binds DNA to switch genes on and off. And the VDR is expressed abundantly in the hair follicle: in the outer root sheath keratinocytes, in the matrix cells, and in the dermal papilla, with expression varying across the hair cycle and peaking around the transitions between phases (Amor et al., 2010).

A receptor that is concentrated in the follicle and that fluctuates with the follicle’s own cycle is not decorative. It is doing something. The question is what.

The Knockout Model That Everyone Cites — and What It Actually Proves

Here is the finding that launched a thousand supplement claims.

When researchers genetically delete the vitamin D receptor in mice, the animals develop a striking phenotype: they grow a normal first coat of hair, then shed it and never regrow it, ending up with total alopecia and dermal cysts. The same phenotype appears in humans with hereditary vitamin D–resistant rickets — a rare condition caused by inactivating VDR mutations, in which total scalp and body alopecia is a defining feature (Li et al., 1997; Malloy & Feldman, 2011).

That is a dramatic result, and it establishes something real: VDR signalling is required for the hair follicle to re-enter the growth phase after its first cycle. Once a follicle completes its initial anagen and transitions into catagen and telogen, restarting requires the receptor. Without it, the follicle’s stem cell compartment fails to initiate a new cycle.

Now here is the part almost every popular article omits, and it changes the interpretation completely.

The alopecia in VDR knockout animals is not corrected by giving vitamin D. It is not corrected by normalizing calcium either. Patients with vitamin D–resistant rickets can have their bone disease managed with high-dose calcium and still remain completely bald, because their receptor cannot respond to any amount of ligand. Conversely, mice engineered to lack the enzyme that makes active vitamin D — animals with essentially no hormone but intact receptors — have normal hair (Skorija et al., 2005).

The conclusion is unavoidable and it is the single most important sentence in this article: the follicle needs the VDR protein itself, and much of that requirement appears to be ligand-independent. The receptor functions in the follicle partly as a structural partner in gene-regulatory complexes — including its interaction with the hairless (HR) corepressor — rather than purely as a vitamin D sensor.

So “VDR knockout mice go bald” does not translate to “low vitamin D makes you bald,” and it certainly does not translate to “vitamin D supplements regrow hair.” It tells us the receptor matters enormously. It tells us far less about the hormone.

I want to be honest that this nuance cuts against the simplest version of my own commercial interest. It is still what the literature says.

What the Human Association Studies Show

Set the mouse models aside. What happens when you measure 25-OH vitamin D in real people with hair loss?

Telogen effluvium. Multiple observational studies have found significantly lower serum vitamin D in women with diffuse shedding than in controls. A frequently cited study in Skin Pharmacology and Physiology examined both ferritin and vitamin D in women with telogen effluvium and female pattern hair loss, finding levels lower in the hair loss groups and inversely related to severity (Rasheed et al., 2013).

Female pattern hair loss. The signal here is present but weaker and less consistent than in telogen effluvium. Some case-control studies find lower levels in affected women; others find no meaningful difference after adjusting for age and body mass index. Pattern hair loss is fundamentally an androgen-driven, genetically determined process, and it would be surprising if a vitamin explained much of it.

Alopecia areata. This is where the association is strongest and most biologically coherent. Alopecia areata is an autoimmune condition, vitamin D has well-characterized immunomodulatory effects on T-cell behavior and dendritic cell maturation, and studies consistently report lower serum vitamin D in patients than controls — with several finding an inverse relationship between level and disease severity (Aksu Cerman et al., 2014).

Across all three, the pattern is consistent: lower vitamin D shows up in people with hair loss more often than in people without it. That is a real, replicated observation. What it means is a separate question.

Association Versus Causation: The Part That Requires Discipline

There are at least four ways to explain a correlation between low vitamin D and hair loss that do not involve vitamin D causing hair loss.

Reverse causation and behavior. People with visible hair loss frequently change their behavior — hats, avoiding sun exposure on a thinning crown, spending less time out in public during a distressing period. Less sun means less cutaneous vitamin D synthesis. The hair loss may be lowering the vitamin D.

Shared upstream causes. Chronic illness, autoimmune disease, malabsorption, obesity, poor diet, and psychological stress each independently lower vitamin D and independently trigger hair shedding. Both findings can be downstream of the same underlying problem.

Vitamin D as an inflammation marker. Serum 25-OH vitamin D falls during acute inflammatory states, which means a low level sometimes reflects illness rather than nutritional status.

Publication bias. Studies that find an association are more likely to be published than studies that do not — and this literature is dominated by small case-control designs from a handful of centers.

Then there is the test that would settle it: randomized controlled trials of vitamin D supplementation with hair outcomes. The honest summary is that these are few, small, heterogeneous in dose and duration, and mixed in result. There is reasonable evidence that correcting deficiency helps some patients, particularly in alopecia areata and particularly as an adjunct rather than a monotherapy. There is no good evidence that supplementing a person whose level is already adequate does anything for their hair.

That is an unsatisfying answer. It is also the accurate one, and I would rather give you an accurate unsatisfying answer than a confident wrong one.

Testing: Which Number, and Which Target

If you take one practical instruction from this article, take this one: the correct test is serum 25-hydroxyvitamin D (25-OH D). Not 1,25-dihydroxyvitamin D. The active form is tightly regulated and can appear normal or even elevated in genuine deficiency, which makes it actively misleading as a screening test. If a lab order or a direct-to-consumer panel gives you 1,25, it is answering a different question.

On interpretation, there is a genuine and unresolved disagreement between expert bodies, and you deserve to know it exists:

The Institute of Medicine (now NASEM) concluded in 2011 that 20 ng/mL is sufficient for bone health in the general population, framing its recommendations around skeletal outcomes at a population level (IOM, 2011).
The Endocrine Society clinical practice guideline defines deficiency as below 20 ng/mL, insufficiency as 21–29 ng/mL, and sufficiency as 30 ng/mL and above, and is oriented toward patients at risk rather than the general population (Holick et al., 2011).

Most hair-focused clinicians work toward the 30–50 ng/mL range and consider anything under 30 worth correcting, on the reasoning that follicle keratinocytes are among the tissues expressing VDR and that the skeletal threshold was never designed with them in mind. I will be candid that this preference is extrapolation, not trial-proven. It is defensible, and it is not proven.

What I will say without hedging: if your level is under 20, that is a genuine deficiency with consequences well beyond your hair, and it should be corrected by your physician regardless of what your ponytail is doing.

Why Deficiency Is Nearly Universal in Autoimmune Thyroid Disease

There is a specific population reading this for whom vitamin D is not a marginal issue, and it overlaps heavily with the women who lose hair.

Hashimoto’s thyroiditis and Graves’ disease are consistently associated with low vitamin D status. Studies comparing patients with autoimmune thyroid disease to healthy controls repeatedly find lower 25-OH D levels and higher rates of frank deficiency, with some reporting an inverse relationship between vitamin D level and anti-thyroid antibody titers (Kivity et al., 2011).

The proposed mechanisms run in both directions. Vitamin D modulates regulatory T-cell function and dampens the Th1-skewed immune responses characteristic of autoimmune thyroiditis, which suggests deficiency could permit autoimmunity. But autoimmune and inflammatory states also lower circulating vitamin D, so the arrow may point the other way. Genetic variation in VDR itself has been associated with autoimmune thyroid disease risk, which muddies it further.

For a woman losing hair, the practical significance is straightforward and does not depend on resolving that debate: hypothyroidism is a well-established cause of diffuse hair loss, autoimmune thyroid disease is its most common cause in developed countries, and vitamin D deficiency travels with it. If you are shedding, a full thyroid panel — TSH, free T4, free T3, and anti-TPO antibodies — belongs on the same requisition as your 25-OH D and your ferritin. These are not three separate investigations. They are one.

Toxicity: Why “More” Is Not Free

Vitamin D is fat-soluble. This is not a technicality; it is the entire safety story.

Water-soluble vitamins in excess are largely excreted in urine — expensive, but forgiving. Fat-soluble vitamins accumulate in adipose tissue and liver, and vitamin D has a long half-life. Excess intake does not wash out. It builds up over months, and the consequences are not cosmetic.

Vitamin D toxicity causes hypercalcemia — elevated blood calcium — which produces nausea, vomiting, constipation, excessive thirst and urination, confusion, kidney stones, calcification of soft tissue including blood vessels and kidneys, cardiac arrhythmias, and in severe cases acute kidney injury. Documented cases have arisen from over-the-counter high-dose products, from mislabeled or misformulated supplements, and — importantly — from well-intentioned over-correction of a diagnosed deficiency continued far longer than intended (Galior et al., 2018).

Two additional cautions:

Certain conditions dramatically increase risk. Sarcoidosis, tuberculosis, some lymphomas, and other granulomatous diseases cause unregulated conversion of vitamin D to its active form. In these patients, ordinary supplement doses can produce dangerous hypercalcemia. This is not rare enough to ignore.

“High-dose weekly” products are prescription-strength thinking sold at retail. A 50,000 IU capsule is a therapeutic dose intended for supervised, time-limited repletion with follow-up labs. Taken indefinitely because it seemed to be working, it is a slow accumulation with no feedback signal until symptoms appear.

So here is the same rule I apply to iron, for the same underlying reason: test, don’t guess. Get the 25-OH D level. Let your physician choose the repletion dose based on how low it actually is. Re-test in roughly 8–12 weeks to confirm you have landed in range and not overshot it. Then move to a maintenance dose — or to sensible sun exposure and diet — rather than staying on a repletion dose forever.

A nutrient your body cannot excrete is not a nutrient to experiment with.

The Bottom Line

The vitamin D receptor is genuinely required for hair follicle cycling — that part of the science is solid, elegant, and confirmed in both animal models and a human genetic disease. But the requirement appears to be substantially for the receptor protein, not the vitamin, which is exactly why “VDR knockout mice go bald” cannot be translated into “supplements regrow hair.”

In human studies, low vitamin D shows up more often in people with telogen effluvium, female pattern hair loss, and especially alopecia areata than in people without hair loss. That association is real and replicated, but it is confounded by behavior, illness, inflammation, and shared upstream causes, and the supplementation trials that would settle causation are small, sparse, and mixed.

The reasonable clinical position, then: test your 25-OH vitamin D, correct a genuine deficiency under physician supervision, do not megadose, and do not expect vitamin D alone to solve your hair. It belongs on the requisition beside ferritin and a full thyroid panel — three tests that together explain a large share of unexplained shedding in women, and that almost nobody orders together.

Your hair is not waiting on a single capsule. But if one of your foundations is genuinely missing, it is worth knowing which.

Dr. Susan Lin’s Clinical Perspective

“Vitamin D is the most over-promised and under-tested nutrient in hair medicine at once. The receptor biology is real — a follicle cannot re-enter anagen without a functioning VDR, and the human genetic condition proves it. But that same evidence shows the requirement is largely ligand-independent, which means the knockout mouse everyone quotes is not the argument for supplementation people think it is. What I actually do in practice is simple: I order 25-OH vitamin D alongside ferritin and a full thyroid panel, because those three travel together in the shedding patient and because autoimmune thyroid disease and low vitamin D are near-constant companions. Then I correct what is genuinely low, at a dose chosen for that patient, and I re-test. Vitamin D accumulates. Test, don’t guess — with this one, guessing high causes hypercalcemia, not disappointment.”

— Dr. Susan F. Lin, M.D., Physician Formulator, MD HAIR

Mechanism Spotlight: VDR, the Hairless Corepressor, and the Anagen Restart

The follicle’s dependence on the vitamin D receptor is most visible at one specific moment: the transition out of telogen into a new growth phase.

After a follicle completes its first anagen and cycles into catagen, restarting requires a coordinated reprogramming of gene expression in the bulge stem cell compartment — the reservoir that supplies cells for each new cycle. VDR participates in that reprogramming as part of a nuclear receptor complex, working alongside the hairless (HR) gene product, a corepressor that silences specific target genes at the right moment in the cycle. Notably, mutations in HR produce atrichia with papular lesions, a human alopecia phenotype strikingly similar to that of VDR mutation — two different genes converging on the same regulatory complex and producing nearly the same failure of follicle regeneration (Malloy & Feldman, 2011).

The decisive experiment is the one that gets left out of consumer articles. Mice lacking the enzyme that produces active vitamin D — no hormone, intact receptor — have normal hair. Mice lacking the receptor go permanently bald regardless of hormone levels (Skorija et al., 2005; Li et al., 1997). The follicle needs the receptor as a structural participant in gene regulation more than it needs the ligand that activates it elsewhere in the body.

This is why the honest formulator’s position on vitamin D is narrower than the marketing position: correcting a documented deficiency is sound medicine with real systemic benefit, and it removes a plausible obstacle to normal cycling. It is not a growth stimulus, and no amount of receptor biology makes it one.

MD HAIR Product Recommendation

MD Nutri Hair™ — Hair Density Supplement

I will be as precise here as I was about iron: MD Nutri Hair™ is not vitamin D therapy — it contains no vitamin D — and it is not a substitute for a 25-OH vitamin D test or physician-supervised repletion. If your level is 14 ng/mL, that correction is a medical decision made with your doctor at a dose chosen for you — precisely because vitamin D accumulates and over-correction causes hypercalcemia rather than merely wasted money.

What MD Nutri Hair™ addresses is the part of the follicle’s internal demand that does not require a prescription-strength intervention. The formula anchors on lilac stem-cell extract standardized for verbascoside. In controlled laboratory studies, that molecule — sourced in the published work from Acanthus rather than lilac, the same compound from a different plant — prevented testosterone-induced death of human dermal papilla cells, the cells at the base of the follicle, and reduced the release of pro-inflammatory signals including IL-1α, IL-6, IL-1β and TNF-α (Wisuitiprot et al., 2022). Those are cell studies, not human trials, and the authors state that clinical study is still needed. One capsule a day. In a 30-day in-office consumer use study of MD Nutri Hair™ (30 subjects, outcomes self-reported), 95% saw improved hair appearance, 90% reported better manageability, and 75% reported increased fullness. Individual results vary.

Drug-free and hormone-free, formulated by Dr. Susan F. Lin, M.D. — physician-formulated since 2008 — and made in the USA in FDA-registered, GMP-compliant facilities by La Cañada Ventures, Inc. If you are taking prescription vitamin D or managing any medical condition — particularly a granulomatous disease such as sarcoidosis — review this or any supplement with your physician first. Because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation.

A note on authenticity: genuine MD HAIR and MD Nutri Hair™ products are sold only through mdhair.com, md-factor.com, and the official La Cañada Ventures, Inc. stores on Amazon and Walmart. We cannot verify the storage, handling, or authenticity of products bought anywhere else.

References

Li YC, Pirro AE, Amling M, et al. (1997). Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proceedings of the National Academy of Sciences, 94(18), 9831–9835. PubMed
Skorija K, Cox M, Sisk JM, et al. (2005). Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Molecular Endocrinology, 19(4), 855–862. PubMed
Malloy PJ, Feldman D. (2011). The role of vitamin D receptor mutations in the development of alopecia. Molecular and Cellular Endocrinology, 347(1–2), 90–96. PubMed
Amor KT, Rashid RM, Mirmirani P. (2010). Does D matter? The role of vitamin D in hair disorders and hair follicle cycling. Dermatology Online Journal, 16(2), 3. PubMed
Rasheed H, Mahgoub D, Hegazy R, et al. (2013). Serum ferritin and vitamin D in female hair loss: do they play a role? Skin Pharmacology and Physiology, 26(2), 101–107. PubMed
Aksu Cerman A, Sarikaya Solak S, Kivanc Altunay I. (2014). Vitamin D deficiency in alopecia areata. British Journal of Dermatology, 170(6), 1299–1304. PubMed
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 96(7), 1911–1930. PubMed
Institute of Medicine. (2011). Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press. NationalAcademies.org
Kivity S, Agmon-Levin N, Zisappl M, et al. (2011). Vitamin D and autoimmune thyroid diseases. Cellular & Molecular Immunology, 8(3), 243–247. PubMed
Galior K, Grebe S, Singh R. (2018). Development of vitamin D toxicity from overcorrection of vitamin D deficiency: a review of case reports. Nutrients, 10(8), 953. PubMed
Wisuitiprot V, et al. (2022). Effects of Acanthus ebracteatus Vahl. extract and verbascoside on human dermal papilla and murine macrophage. Scientific Reports, 12, 1491. PubMed

Dr. Susan F. Lin, M.D. is the physician formulator behind MD HAIR, a line of drug-free, clinically informed hair and scalp products by La Cañada Ventures, Inc., physician-formulated since 2008 under the MD® mark. MD HAIR topical products are cosmetics; they are not intended to diagnose, treat, cure, or prevent any disease. MD Nutri Hair™ is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for educational purposes and does not constitute medical advice. Do not begin high-dose vitamin D supplementation without blood testing and physician supervision, and do not start, stop, or change any prescribed medication without consulting your own physician. Individual results vary. Because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation.